Latest Advances in Lung Cancer Research

A study conducted by Penn Medicine researchers has shown that some patients with advanced lung cancer may benefit from a shorter duration of immunotherapy treatment, a type of cancer treatment that helps the immune system fight cancer cells.

The AI tool can identify whether abnormal growths found on CT scans are cancerous, improving early detection and potentially make cancer treatment more successful.

New treatments like immunotherapy and targeted therapy are improving post-surgery outcomes for lung cancer, with research ongoing to optimize these methods.

A deep learning model called Sybil has been developed to predict an individual’s future lung cancer risk from a low-dose chest computed tomography scan.

New report shows that many of the tumors with low PD-L1 have developed genetic strategies that avoid immunotherapies.

Pre-surgical immunotherapy along with post-surgical immunotherapy significantly improved survival compared to chemotherapy alone for patients with operable non-small cell lung cancer.

The inflammation associated with lung cancer and depression may impact survival, despite treatments like immunotherapy and targeted therapies.

Estimated rates of lung cancer screening with low-dose CT were extremely low among eligible patients across insurance types in 2017.

The phase 3 Pragmatica-Lung study has broader eligibility criteria than many other trials, expanding access to more patients and clinicians.

The researchers hope the findings of ‘ever-changing’ nature of lung cancer could help doctors to tailor treatments for individual patients.

Keytruda plus chemotherapy before surgery and as single agent after improved outcomes for patients with resectable non-small cell lung cancer.

Patients with early-stage EGFR-mutated non-small cell lung cancer benefited from treatment with osimertinib, results of the phase 3 ADAURA trial showed.